Regeneron 'Kickbacks' Boosted Eylea Profits, Insurer Says
By Lauren Berg · April 4, 2022, 10:46 PM EDT
Regeneron Pharmaceuticals has illegally cornered the market for an eye disease treatment over a competitor's cheaper drug in a kickback scheme with a charity, reaping billions of dollars in annual revenue...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login